Beta Pharma describes new 1,5-naphthyridine derivatives as KRAS oncoprotein inhibitors
May 30, 2024
Beta Pharma Inc. has presented 1,5-naphthyridine derivatives acting as GTPase KRAS (G12D mutant) and/or (G12C mutant) inhibitors and thus reported to be useful for the treatment of cancer.